Your search for non small cell lung cancer returned 26 results

The designation is supported by data from the ongoing phase 2 KEYNOTE-942 study, which included 157 patients with stage III/IV melanoma following complete resection.

The sBLA was supported by data from the phase 3 TOPAZ-1 trial.

Sintilimab is an investigational programmed death receptor-1 (PD-1) inhibitor.

The decision was made to withdraw the application after the Companies and the FDA were not able to align on certain postmarketing studies.

Pemrydi RTU is expected to be available in the first quarter of 2024.

A regulatory decision is expected on November 27, 2023.

Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody.

The ready-to-dilute formulation was developed to eliminate the reconstitution step with Alimta.

Krazati is a highly selective and potent oral small molecule inhibitor of KRASG12C.

The approval was based on data from a phase 3 POSEIDON study.